Asia Union Investments

Asia Union Investments is a strategic investment holding company that serves as the primary ownership vehicle for the founders of GenScript Biotech Corporation. Through its controlling interest in GenScript, the company oversees a vast ecosystem of life science services, including gene synthesis, protein engineering, and peptide synthesis. Furthermore, Asia Union Investments is a major stakeholder in Legend Biotech, a leading developer of innovative cell therapies, most notably the FDA-approved CAR-T therapy Carvykti. The company's portfolio also includes Asia Union Pharmaceuticals, which focuses on traditional pharmaceutical manufacturing and distribution in the Asian market.